Publication Name	World Journal of Hepatology
Manuscript ID	21276
Country	Russia

Received	2015-07-03 08:37
Peer-Review Started	2015-07-06 11:24
To Make the First Decision	2015-08-26 15:10
Return for Revision	2015-08-31 16:33
Revised	2015-10-07 06:55
Second Decision	2015-12-08 13:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-12-23 13:05
Articles in Press	2015-12-23 13:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-02-17 15:43
Publish the Manuscript Online	2016-02-22 15:38

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Randomized Controlled Trial
Article Title	Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia
Manuscript Source	Unsolicited Manuscript
All Author List	Vasily Isakov, Igor Nikitin, Vladimir Chulanov, Pavel Ogurtsov, Ekaterina Lukyanova, Jianmin Long, Janice Wahl and Frans A Helmond; The P08160 Trial Investigators
Funding Agency and Grant Number	Funding Agency Grant Number Merck & Co., Inc., Kenilworth, NJ, United States
Corresponding Author	Vasily Isakov, professor, Department of Gastroenterology and Hepatology, Institute of Nutrition, Kashirskoe Shosse 21, Moscow 115446, Russia. vasily.isakov@gmail.com
Key Words	hepatitis C virus; boceprevir; peginterferon; ribavirin; randomized; clinical trial; sustained virologic response
Core Tip	Compared to the standard-of care treatment with peginterferon and ribavirin (PR), addition of boce-previr to PR results in a significant increase in rates of sustained virologic response achieved with substantially shorter treatment durations across a broad cross-section of patients with chronic hepatitis C virus infection in Russia.
Publish Date	2016-02-22 15:38
Citation	Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA; the P08160 Trial Investigators. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol 2016; 8(6): 331-339
URL	http://www.wjgnet.com/1948-5182/full/v8/i6/331.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i6.331

Full Article (PDF)	WJH-8-331.pdf
Full Article (Word)	WJH-8-331.doc
Manuscript File	21276-Review.docx
Answering Reviewers	21276-Answering reviewers.pdf
Audio Core Tip	21276-Audio core tip.mp3
Biostatistics Review Certificate	21276-Biostatistics statement.pdf
Clinical Trial Registration Statement	21276-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	21276-Conflict-of-interest statement.pdf
Copyright License Agreement	21276-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	21276-Clinical trial registration statement.pdf
Institutional Review Board Approval Form or Document	21276-Institutional review board statement.pdf
Supplementary Material	Supplementary_Material_20150703020114.docx
Peer-review Report	21276-Peer-review(s).pdf
Scientific Misconduct Check	21276-Scientific misconduct check.pdf
Scientific Editor Work List	21276-Scientific editor work list.pdf